BANCO MACRO SA-ADR (BMA) Fundamental Analysis & Valuation

NYSE:BMA • US05961W1053

Current stock price

77.46 USD
-0.45 (-0.58%)
At close:
77.46 USD
0 (0%)
After Hours:

This BMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BMA Profitability Analysis

1.1 Basic Checks

  • Each year in the past 5 years BMA has been profitable.
  • In multiple years BMA reported negative operating cash flow during the last 5 years.
BMA Yearly Net Income VS EBIT VS OCF VS FCFBMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T

1.2 Ratios

  • BMA has a Return On Assets of 1.18%. This is in the better half of the industry: BMA outperforms 72.89% of its industry peers.
  • With a Return On Equity value of 5.26%, BMA is not doing good in the industry: 78.68% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA 1.18%
ROE 5.26%
ROIC N/A
ROA(3y)3.94%
ROA(5y)3.32%
ROE(3y)13.6%
ROE(5y)12.11%
ROIC(3y)N/A
ROIC(5y)N/A
BMA Yearly ROA, ROE, ROICBMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • With a Profit Margin value of 6.04%, BMA is not doing good in the industry: 89.47% of the companies in the same industry are doing better.
  • BMA's Profit Margin has declined in the last couple of years.
  • BMA does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 6.04%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-13.03%
PM growth 5Y-20.33%
GM growth 3YN/A
GM growth 5YN/A
BMA Yearly Profit, Operating, Gross MarginsBMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1

2. BMA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, BMA has about the same amount of shares outstanding.
  • The number of shares outstanding for BMA has been reduced compared to 5 years ago.
  • Compared to 1 year ago, BMA has a worse debt to assets ratio.
BMA Yearly Shares OutstandingBMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BMA Yearly Total Debt VS Total AssetsBMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T

2.2 Solvency

  • BMA has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.29, BMA is doing worse than 65.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BMA Yearly LT Debt VS Equity VS FCFBMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
BMA Yearly Current Assets VS Current LiabilitesBMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T

6

3. BMA Growth Analysis

3.1 Past

  • BMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.60%, which is quite good.
  • The Earnings Per Share has been growing by 61.36% on average over the past years. This is a very strong growth
  • Looking at the last year, BMA shows a very negative growth in Revenue. The Revenue has decreased by -32.37% in the last year.
  • The Revenue has been growing by 85.69% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.6%
EPS 3Y82.29%
EPS 5Y61.36%
EPS Q2Q%-0.43%
Revenue 1Y (TTM)-32.37%
Revenue growth 3Y109.61%
Revenue growth 5Y85.69%
Sales Q2Q%207.11%

3.2 Future

  • BMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 69.33% yearly.
  • Based on estimates for the next years, BMA will show a small growth in Revenue. The Revenue will grow by 7.67% on average per year.
EPS Next Y119.08%
EPS Next 2Y69.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.89%
Revenue Next 2Y7.67%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BMA Yearly Revenue VS EstimatesBMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1T 2T 3T 4T 5T
BMA Yearly EPS VS EstimatesBMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2K 4K 6K 8K 10K

1

4. BMA Valuation Analysis

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
BMA Price Earnings VS Forward Price EarningsBMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMA Per share dataBMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share

4.3 Compensation for Growth

  • BMA's earnings are expected to grow with 69.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.33%
EPS Next 3YN/A

0

5. BMA Dividend Analysis

5.1 Amount

  • BMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BMA Fundamentals: All Metrics, Ratios and Statistics

BANCO MACRO SA-ADR

NYSE:BMA (4/2/2026, 8:10:07 PM)

After market: 77.46 0 (0%)

77.46

-0.45 (-0.58%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)02-25
Earnings (Next)05-26
Inst Owners32.07%
Inst Owner Change16.1%
Ins OwnersN/A
Ins Owner Change0%
Market Cap4.87B
Revenue(TTM)4.56T
Net Income(TTM)275.06B
Analysts83.33
Price TargetN/A
Short Float %1.62%
Short Ratio1.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP98.31%
Div Incr Years2
Div Non Decr Years2
Ex-Date02-19
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-64.37%
Min EPS beat(2)-136.43%
Max EPS beat(2)7.69%
EPS beat(4)2
Avg EPS beat(4)-33.92%
Min EPS beat(4)-136.43%
Max EPS beat(4)17.19%
EPS beat(8)3
Avg EPS beat(8)-36.25%
EPS beat(12)4
Avg EPS beat(12)151.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)52.03%
Min Revenue beat(2)12.7%
Max Revenue beat(2)91.36%
Revenue beat(4)2
Avg Revenue beat(4)14.25%
Min Revenue beat(4)-23.64%
Max Revenue beat(4)91.36%
Revenue beat(8)5
Avg Revenue beat(8)27.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)345.52%
EPS NQ rev (3m)62.84%
EPS NY rev (1m)-17.76%
EPS NY rev (3m)-21.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)N/A
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpSN/A
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.18%
ROE 5.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 6.04%
GM N/A
FCFM N/A
ROA(3y)3.94%
ROA(5y)3.32%
ROE(3y)13.6%
ROE(5y)12.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-13.03%
PM growth 5Y-20.33%
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 3.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)2.74%
Cap/Sales(5y)3.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.6%
EPS 3Y82.29%
EPS 5Y61.36%
EPS Q2Q%-0.43%
EPS Next Y119.08%
EPS Next 2Y69.33%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-32.37%
Revenue growth 3Y109.61%
Revenue growth 5Y85.69%
Sales Q2Q%207.11%
Revenue Next Year3.89%
Revenue Next 2Y7.67%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-638.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-234.36%
OCF growth 3YN/A
OCF growth 5YN/A

BANCO MACRO SA-ADR / BMA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BANCO MACRO SA-ADR (BMA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMA.


What is the valuation status for BMA stock?

ChartMill assigns a valuation rating of 1 / 10 to BANCO MACRO SA-ADR (BMA). This can be considered as Overvalued.


What is the profitability of BMA stock?

BANCO MACRO SA-ADR (BMA) has a profitability rating of 2 / 10.


Can you provide the financial health for BMA stock?

The financial health rating of BANCO MACRO SA-ADR (BMA) is 1 / 10.